Published October 1, 2016 | Version v1
Journal article

Stereotactic Radiosurgery for Brainstem Metastases: An International Cooperative Study to Define Response and Toxicity

  • 1. Department of Radiation Oncology, University of Virginia, Charlottesville, Virginia (United States)
  • 2. Department of Neurosurgery, Neurological Institute, Taipei Veteran General Hospital, Taipei, Taiwan (China)
  • 3. Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (United States)
  • 4. Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania (United States)
  • 5. Department of Radiation and Stereotactic Neurosurgery, Na Homolce Hospital, Prague (Czech Republic)
  • 6. Department of Neurosurgery, New York University Lagone Medical Center, New York, New York (United States)
  • 7. Department of Radiation Oncology, Beaumont Health System, Royal Oak, Michigan (United States)
  • 8. Division of Neurosurgery, Université de Sherbrooke, Centre de recherche du CHUS, Sherbrooke, Québec (Canada)
  • 9. Department of Neurosurgery, Cleveland Clinic, Cleveland, Ohio (United States)
  • 10. Departments of Neurosurgery and Radiation Oncology, West Virginia University, Morgantown, West Virginia (United States)

Description

Purpose: To pool data across multiple institutions internationally and report on the cumulative experience of brainstem stereotactic radiosurgery (SRS). Methods and Materials: Data on patients with brainstem metastases treated with SRS were collected through the International Gamma Knife Research Foundation. Clinical, radiographic, and dosimetric characteristics were compared for factors prognostic for local control (LC) and overall survival (OS) using univariate and multivariate analyses. Results: Of 547 patients with 596 brainstem metastases treated with SRS, treatment of 7.4% of tumors resulted in severe SRS-induced toxicity (grade ≥3, increased odds with increasing tumor volume, margin dose, and whole-brain irradiation). Local control at 12 months after SRS was 81.8% and was improved with increasing margin dose and maximum dose. Overall survival at 12 months after SRS was 32.7% and impacted by age, gender, number of metastases, tumor histology, and performance score. Conclusions: Our study provides additional evidence that SRS has become an option for patients with brainstem metastases, with an excellent benefit-to-risk ratio in the hands of experienced clinicians. Prior whole-brain irradiation increases the risk of severe toxicity in brainstem metastasis patients undergoing SRS.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.ijrobp.2016.06.009

Additional details

Identifiers

DOI
10.1016/j.ijrobp.2016.06.009;
PII
S0360-3016(16)30320-0;

Publishing Information

Journal Title
International Journal of Radiation Oncology, Biology and Physics
Journal Volume
96
Journal Issue
2
Journal Page Range
p. 280-288
ISSN
0360-3016
CODEN
IOBPD3

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
48094238
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
DOSIMETRY; MULTIVARIATE ANALYSIS; NEOPLASMS; PATIENTS; RADIATION DOSES; RADIATION HAZARDS; RADIOTHERAPY; SURGERY; TOXICITY
Descriptors DEC
DISEASES; DOSES; HAZARDS; HEALTH HAZARDS; MATHEMATICS; MEDICINE; NUCLEAR MEDICINE; RADIOLOGY; STATISTICS; THERAPY

Optional Information

Copyright
Copyright (c) 2016 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.